

## 6 Literaturverzeichnis

Abbott N.J. und Romero I.A. (1996) Transporting therapeutics across the blood-brain barrier. *Mol Med Today* 2, 106-113.

Aggerbeck L.P., Wetterau J.R., Weisgraber K.H., Wu C.S., und Lindgren F.T. (1988) Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. *J Biol Chem* 263, 6249-6258.

Allen T.M. und Everest J.M. (1983) Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. *J Pharmacol Exp Ther* 226, 539-544.

Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., und Kreuter J. (1997) Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylecyanoacrylate nanoparticles. *Pharm Res* 14, 325-328.

Arnold K., Innerarity T., Pitas R. E., and Mahley R. W. (1992) Lipoprotein-receptor interactions, in *Lipoprotein Analysis* (Converse C. A. and Skinner E. R., eds.), pp. 145-168. Oxford University Press.

Azmin M.N., Stuart J.F., und Florence A.T. (1985) The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. *Cancer Chemother Pharmacol* 14, 238-242.

Baillie G., Owens M.D., und Halbert G.W. (2002) A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro. *J Lipid Res* 43, 69-73.

Balazs Z., Panzenboeck U., Hammer A., Sovic A., Quehenberger O., Malle E., und Sattler W. (2004) Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. *J Neurochem* 89, 939-950.

Balda M.S., Fallon M.B., Van Itallie C.M., und Anderson J.M. (1992) Structure, regulation, and pathophysiology of tight junctions in the gastrointestinal tract. *Yale J Biol Med* 65, 725-735.

Bangham A.D., Standish M.M., und Watkins J.C. (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. *J Mol Biol* 13, 238-252.

Bartus R.T., Elliott P., Hayward N., Dean R., McEwen E.L., und Fisher S.K. (1996) Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system. *Immunopharmacology* 33, 270-278.

Bauer B. (2002) In vitro Zellkulturmodelle der Blut-Hirn Schranke zur Untersuchung der Permeation und P-Glycoprotein-Interaktion von Arzneistoffe.

Bechinger B. (2001) Membrane insertion and orientation of polyalanine peptides: a <sup>15</sup>N solid-state NMR spectroscopy investigation. *Biophys J* 81, 2251-2256.

Begley D.J. (1996) The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. *J Pharm Pharmacol* 48, 136-146.

- Belting M. (2003) Heparan sulfate proteoglycan as a plasma membrane carrier. *Trends Biochem Sci* 28, 145-151.
- Bendas G. (2001) Immunoliposomes: a promising approach to targeting cancer therapy. *BioDrugs* 15, 215-224.
- Betz A.L. und Goldstein G.W. (1978) Polarity of the blood-brain barrier: neutral amino acid transport into isolated brain capillaries. *Science* 202, 225-227.
- Bickel U., Yoshikawa T., Landaw E.M., Faull K.F., und Pardridge W.M. (1993) Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. *Proc Natl Acad Sci U S A* 90, 2618-2622.
- Boeckler C., Frisch B., Muller S., und Schuber F. (1996) Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes. *J Immunol Methods* 191, 1-10.
- Boettcher C.J.F., Van Gent C.M., und Pries C. (1961) A rapid and sensitive sub-micro phosphorus determination. *Analytica Chimica Acta* 24, 203-204.
- Bonte F. und Juliano R.L. (1986) Interactions of liposomes with serum proteins. *Chem Phys Lipids* 40, 359-372.
- Borlongan C.V. und Emerich D.F. (2003) Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. *Brain Res Bull* 60, 297-306.
- Bradford M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72, 248-254.
- Broadwell R.D. (1989) Transcytosis of macromolecules through the blood-brain barrier: a cell biological perspective and critical appraisal. *Acta Neuropathol (Berl)* 79, 117-128.
- Broadwell R.D., Baker-Cairns B.J., Friden P.M., Oliver C., und Villegas J.C. (1996) Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. *Exp Neurol* 142, 47-65.
- Brown M.S. und Goldstein J.L. (1986) A receptor-mediated pathway for cholesterol homeostasis. *Science* 232, 34-47.
- Cardin A.D., Hirose N., Blankenship D.T., Jackson R.L., Harmony J.A., Sparrow D.A., und Sparrow J.T. (1986) Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. *Biochem Biophys Res Commun* 134, 783-789.
- Cerletti A., Drewe J., Fricker G., Eberle A.N., und Huwyler J. (2000) Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. *J Drug Target* 8, 435-446.
- Chattopadhyay A. und London E. (1987) Parallax Method for Direct Measurement of Membrane Penetration Depth Utilizing Fluorescence Quenching by Spin-Labeled Phospholipids. *Biochemistry* 26, 39-45.

- Chen Y.H., Yang J.T., und Martinez H.M. (1972) Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. *Biochemistry* 11, 4120-4131.
- Console S., Marty C., Garcia-Echeverria C., Schwendener R., und Ballmer-Hofer K. (2003) Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. *J Biol Chem* 278, 35109-35114.
- Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., und Bertino J.R. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. *Proc Natl Acad Sci U S A* 86, 695-698.
- Cotton A. (1896) *Ann Chim Phys* 8, 347.
- Crone C. und Olesen S.P. (1982) Electrical resistance of brain microvascular endothelium. *Brain Res* 241, 49-55.
- Croy J.E., Brandon T., und Komives E.A. (2004) Two apolipoprotein E mimetic peptides, ApoE(130-149) and ApoE(141-155)<sub>2</sub>, bind to LRP1. *Biochemistry* 43, 7328-7335.
- Dagar S., Krishnadas A., Rubinstein I., Blend M.J., und Onyuksel H. (2003) VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. *J Control Release* 91, 123-133.
- Danik M., Champagne D., Petit-Turcotte C., Beffert U., und Poirier J. (1999) Brain lipoprotein metabolism and its relation to neurodegenerative disease. *Crit Rev Neurobiol* 13, 357-407.
- Dathe M., Nikolenko H., Klose J., und Bienert M. (2004) Cyclization increases the antimicrobial activity and selectivity of arginine- and tryptophan-containing hexapeptides. *in press*.
- Dathe M., Meyer J., Beyermann M., Maul B., Hoischen C., und Bienert M. (2002) General aspects of peptide selectivity towards lipid bilayers and cell membranes studied by variation of the structural parameters of amphipathic helical model peptides. *Biochim Biophys Acta* 1558, 171-186.
- Datta G., Chaddha M., Garber D.W., Chung B.H., Tytler E.M., Dashti N., Bradley W.A., Gianturco S.H., und Anantharamaiah G.M. (2000) The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. *Biochemistry* 39, 213-220.
- Datta G., Garber D.W., Chung B.H., Chaddha M., Dashti N., Bradley W.A., Gianturco S.H., und Anantharamaiah G.M. (2001) Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. *J Lipid Res* 42, 959-966.
- de Vries H.E., Breedveld B., Kuiper J., de Boer A.G., Van Berkel T.J., und Breimer D.D. (1995) High-density lipoprotein and cerebral endothelial cells in vitro: interactions and transport. *Biochem Pharmacol* 50, 271-273.
- Deetjen P. and Speckmann E. J. (1999) *Physiologie*, Urban & Fischer, München.

- Deguchi Y., Okutsu H., Okura T., Yamada S., Kimura R., Yuge T., Furukawa A., Morimoto K., Tachikawa M., Ohtsuki S., Hosoya K., und Terasaki T. (2002) Internalization of basic fibroblast growth factor at the mouse blood-brain barrier involves perlecan, a heparan sulfate proteoglycan. *J Neurochem* 83, 381-389.
- Dehouck B., Dehouck M.P., Fruchart J.C., und Cecchelli R. (1994) Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. *J Cell Biol* 126, 465-473.
- Dehouck B., Fenart L., Dehouck M.P., Pierce A., Torpier G., und Cecchelli R. (1997) A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. *J Cell Biol* 138, 877-889.
- Deli M.A. und Joo F. (1996) Cultured vascular endothelial cells of the brain. *Keio J Med* 45, 183-198.
- Doolittle N.D., Abrey L.E., Ferrari N., Hall W.A., Laws E.R., McLendon R.E., Muldoon L.L., Peereboom D., Peterson D.R., Reynolds C.P., Senter P., und Neuwelt E.A. (2002) Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium. *Clin Cancer Res* 8, 1702-1709.
- Drewes L.R. (1999) What is the blood-brain barrier? A molecular perspective. Cerebral vascular biology. *Adv Exp Med Biol* 474, 111-122.
- Drin G., Rousselle C., Scherrmann J.M., Rees A.R., und Temsamani J. (2002) Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. *AAPS PharmSci* 4, E26.
- Drion N., Lemaire M., Lefauconnier J.M., und Scherrmann J.M. (1996) Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. *J Neurochem* 67, 1688-1693.
- Durlu Y.K. und Tamai M. (1997) Transplantation of retinal pigment epithelium using viable cryopreserved cells. *Cell Transplant* 6, 149-162.
- Duzgune&scetil, N, und Nir S. (1999) Mechanisms and kinetics of liposome-cell interactions. *Adv Drug Deliv Rev* 40, 3-18.
- Dyer C.A., Cistola D.P., Parry G.C., und Curtiss L.K. (1995) Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor. *J Lipid Res* 36, 80-88.
- Dyer C.A. und Curtiss L.K. (1991) A synthetic peptide mimic of plasma apolipoprotein E that binds the LDL receptor. *J Biol Chem* 266, 22803-22806.
- Dyer C.A., Smith R.S., und Curtiss L.K. (1991) Only multimers of a synthetic peptide of human apolipoprotein E are biologically active. *J Biol Chem* 266, 15009-15015.
- Ehrlich P. (1885) *Das Sauerstoffbedürfnis des Organismus. Eine farbenanalytische Studie*, Hirschwald, Berlin.
- Ehrlich P. (1906) The relations existing between chemical constitution, distribution and pharmacological action, in *Collected studies on immunity* pp. 404-443. John Wiley and Sons, Ltd., New York.

- Fenart L., Buee-Scherrer V., Descamps L., Duhem C., Poullain M.G., Cecchelli R., und Dehouck M.P. (1998) Inhibition of P-glycoprotein: rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier. *Pharm Res* 15, 993-1000.
- Fidler I.J., Sone S., Fogler W.E., und Barnes Z.L. (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. *Proc Natl Acad Sci U S A* 78, 1680-1684.
- Fishman J.B., Rubin J.B., Handrahan J.V., Connor J.R., und Fine R.E. (1987) Receptor-mediated transcytosis of transferrin across the blood-brain barrier. *J Neurosci Res* 18, 299-304.
- Forssen E.A. und Tokes Z.A. (1981) Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. *Proc Natl Acad Sci U S A* 78, 1873-1877.
- Friden P.M., Walus L.R., Musso G.F., Taylor M.A., Malfroy B., und Starzyk R.M. (1991) Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. *Proc Natl Acad Sci U S A* 88, 4771-4775.
- Frisch B., Boeckler C., und Schuber F. (1996) Synthesis of short polyoxyethylene-based heterobifunctional cross-linking reagents. Application to the coupling of peptides to liposomes. *Bioconjug Chem* 7, 180-186.
- Fry D.W., White J.C., und Goldman I.D. (1978) Rapid separation of low molecular weight solutes from liposomes without dilution. *Anal Biochem* 90, 809-815.
- Fuchs S.M. und Raines R.T. (2004) Pathway for polyarginine entry into mammalian cells. *Biochemistry* 43, 2438-2444.
- Fukuta M., Okada H., Iinuma S., Yanai S., und Toguchi H. (1994) Insulin fragments as a carrier for peptide delivery across the blood-brain barrier. *Pharm Res* 11, 1681-1688.
- Fullerton S.M., Shirman G.A., Strittmatter W.J., und Matthew W.D. (2001) Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. *Exp Neurol* 169, 13-22.
- Galeano N.F., Milne R., Marcel Y.L., Walsh M.T., Levy E., Ngu'yen T.D., Gleeson A., Arad Y., Witte L., al Haideri M., und . (1994) Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. *J Biol Chem* 269, 511-519.
- Garber D.W., Handattu S., Aslan I., Datta G., Chaddha M., und Anantharamaiah G.M. (2003) Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. *Atherosclerosis* 168, 229-237.
- Gessner A., Olbrich C., Schroder W., Kayser O., und Muller R.H. (2001) The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. *Int J Pharm* 214, 87-91.
- Gherzi-Egea J.F., Minn A., und Siest G. (1988) A new aspect of the protective functions of the blood-brain barrier: activities of four drug-metabolizing enzymes in isolated rat brain microvessels. *Life Sci* 42, 2515-2523.

- Gilbreath M.J., Nacy C.A., Hoover D.L., Alving C.R., Swartz G.M., Jr., und Meltzer M.S. (1985) Macrophage activation for microbicidal activity against *Leishmania major*: inhibition of lymphokine activation by phosphatidylcholine-phosphatidylserine liposomes. *J Immunol* 134, 3420-3425.
- Godfray J. und Estibeiro P. (2003) The potential of antisense as a CNS therapeutic. *Expert Opin Ther Targets* 7, 363-376.
- Goldstein G.W. und Betz A.L. (1983) Recent advances in understanding brain capillary function. *Ann Neurol* 14, 389-395.
- Goldstein J.L., Basu S.K., und Brown M.S. (1983) Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. *Methods Enzymol* 98, 241-260.
- Goldstein J.L. und Brown M.S. (1979) The LDL receptor locus and the genetics of familial hypercholesterolemia. *Annu Rev Genet* 13, 259-289.
- Goti D., Hammer A., Galla H.J., Malle E., und Sattler W. (2000) Uptake of lipoprotein-associated alpha-tocopherol by primary porcine brain capillary endothelial cells. *J Neurochem* 74, 1374-1383.
- Gregoriadis G. (1976) The carrier potential of liposomes in biology and medicine (second of two parts). *N Engl J Med* 295, 765-770.
- Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., und Kreuter J. (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. *Pharm Res* 16, 1564-1569.
- Guo L.S., Hamilton R.L., Goerke J., Weinstein J.N., und Havel R.J. (1980) Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. *J Lipid Res* 21, 993-1003.
- Habgood M.D., Begley D.J., und Abbott N.J. (2000) Determinants of passive drug entry into the central nervous system. *Cell Mol Neurobiol* 20, 231-253.
- Harding J.A., Engbers C.M., Newman M.S., Goldstein N.I., und Zalipsky S. (1997) Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. *Biochim Biophys Acta* 1327, 181-192.
- Havel R.J., EDER H.A., und BRAGDON J.H. (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. *J Clin Invest* 34, 1345-1353.
- Higashi N. und Sunamoto J. (1995) Endocytosis of poly(ethylene oxide)-modified liposome by human lymphoblastoid cells. *Biochim Biophys Acta* 1243, 386-392.
- Huai-Yun H., Secrest D.T., Mark K.S., Carney D., Brandquist C., Elmquist W.F., und Miller D.W. (1998) Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. *Biochem Biophys Res Commun* 243, 816-820.
- Huang C. (1969) Studies on phosphatidylcholine vesicles. Formation and physical characteristics. *Biochemistry* 8, 344-352.

- Huwyler J., Wu D., und Pardridge W.M. (1996) Brain drug delivery of small molecules using immunoliposomes. *Proc Natl Acad Sci U S A* 93, 14164-14169.
- Innerarity T.L., Friedlander E.J., Rall S.C., Jr., Weisgraber K.H., und Mahley R.W. (1983) The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. *J Biol Chem* 258, 12341-12347.
- Innerarity T.L., Pitas R.E., und Mahley R.W. (1979) Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. *J Biol Chem* 254, 4186-4190.
- Innerarity T.L., Pitas R.E., und Mahley R.W. (1986) Lipoprotein-receptor interactions. *Methods Enzymol* 129, 542-565.
- Janosch S., Nicolini C., Ludolph B., Peters C., Volkert M., Hazlet T.L., Gratton E., Waldmann H., und Winter R. (2004) Partitioning of dual-lipidated peptides into membrane microdomains: lipid sorting vs peptide aggregation. *J Am Chem Soc* 126, 7496-7503.
- Janssen A.P., Schiffelers R.M., ten Hagen T.L., Koning G.A., Schraa A.J., Kok R.J., Storm G., und Molema G. (2003) Peptide-targeted PEG-liposomes in anti-angiogenic therapy. *Int J Pharm* 254, 55-58.
- Janzer R.C. und Raff M.C. (1987) Astrocytes induce blood-brain barrier properties in endothelial cells. *Nature* 325, 253-257.
- Jevprasesphant R., Penny J., Attwood D., und D'Emanuele A. (2004) Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. *J Control Release* 97, 259-267.
- Ji Z.S., Fazio S., Lee Y.L., und Mahley R.W. (1994) Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. *J Biol Chem* 269, 2764-2772.
- Joseph M. und Nagaraj R. (1995) Interaction of peptides corresponding to fatty acylation sites in proteins with model membranes. *J Biol Chem* 270, 16749-16755.
- Kachel K., Asuncion-Punzalan E., und London E. (1995) Anchoring of tryptophan and tyrosine analogs at the hydrocarbon-polar boundary in model membrane vesicles: parallax analysis of fluorescence quenching induced by nitroxide-labeled phospholipids. *Biochemistry* 34, 15475-15479.
- Kang Y.S. und Pardridge W.M. (1994) Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin. *Pharm Res* 11, 1257-1264.
- Kenagy R., Bierman E.L., Schwartz S., und Albers J.J. (1984) Metabolism of low density lipoprotein by bovine endothelial cells as a function of cell density. *Arteriosclerosis* 4, 365-371.
- Klibanov A.L., Maruyama K., Torchilin V.P., und Huang L. (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. *FEBS Lett* 268, 235-237.
- Kolset S.O. und Salmivirta M. (1999) Cell surface heparan sulfate proteoglycans and lipoprotein metabolism. *Cell Mol Life Sci* 56, 857-870.

- Kreuter J. (1996) Nanoparticles and microparticles for drug and vaccine delivery. *J Anat* 189 (Pt 3), 503-505.
- Kreuter J., Alyautdin R.N., Kharkevich D.A., und Ivanov A.A. (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). *Brain Res* 674, 171-174.
- Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., und Alyautdin R. (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. *J Drug Target* 10, 317-325.
- Kueltzo L.A. und Middaugh C.R. (2003) Nonclassical transport proteins and peptides: an alternative to classical macromolecule delivery systems. *J Pharm Sci* 92, 1754-1772.
- Kumagai A.K., Eisenberg J.B., und Pardridge W.M. (1987) Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. *J Biol Chem* 262, 15214-15219.
- Le Conte P., Joly V., Saint-Julien L., Gillardin J.M., Carbon C., und Yeni P. (1992) Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. *Am Rev Respir Dis* 145, 424-429.
- Linhardt R. J. (1999) Analysis of Glycosaminoglycans with Polysaccharides Lyases, in *Current Protocols in Molecular Biology* pp. 1-16. Jon Wiley & Sons, Inc.
- Lockman P.R., Mumper R.J., Khan M.A., und Allen D.D. (2002) Nanoparticle technology for drug delivery across the blood-brain barrier. *Drug Dev Ind Pharm* 28, 1-13.
- London E. und Feigenson G.W. (1981) Fluorescence quenching in model membranes. 1. Characterization of quenching caused by a spin-labeled phospholipid. *Biochemistry* 20, 1932-1938.
- Lopez-Barcons L.A., Polo D., Reig F., und Fabra A. (2004) Pentapeptide YIGSR-mediated HT-1080 fibrosarcoma cells targeting of adriamycin encapsulated in sterically stabilized liposomes. *J Biomed Mater Res* 69A, 155-163.
- Lowry O.H., Rosebrough N.J., Farr A.L., und Randall R.J. (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* 193, 265-275.
- Lucarelli M., Borrelli V., Fiori A., Cucina A., Granata F., Potenza R.L., Scarpa S., Cavallaro A., und Strom R. (2002) The expression of native and oxidized LDL receptors in brain microvessels is specifically enhanced by astrocytes-derived soluble factor(s). *FEBS Lett* 522, 19-23.
- Lück M. (1997) Plasmaproteinadsorption als möglicher Schlüsselfaktor für eine kontrollierte Arzneistoffapplikation mit partikulären Trägern.
- Lundberg B., Hong K., und Papahadjopoulos D. (1993) Conjugation of apolipoprotein B with liposomes and targeting to cells in culture. *Biochim Biophys Acta* 1149, 305-312.
- Mahley R.W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science* 240, 622-630.



- Mahley R.W., Innerarity T.L., Rall S.C., Jr., und Weisgraber K.H. (1984) Plasma lipoproteins: apolipoprotein structure and function. *J Lipid Res* 25, 1277-1294.
- Maruyama K. (2002) PEG-immunoliposome. *Biosci Rep* 22, 251-266.
- Maruyama K., Yuda T., Okamoto A., Ishikura C., Kojima S., und Iwatsuru M. (1991) Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. *Chem Pharm Bull (Tokyo)* 39, 1620-1622.
- Marz W., Baumstark M.W., Scharnagl H., Ruzicka V., Buxbaum S., Herwig J., Pohl T., Russ A., Schaaf L., Berg A., und . (1993) Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor. *J Clin Invest* 92, 2922-2933.
- Mayer L.D., Bally M.B., und Cullis P.R. (1986) Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. *Biochim Biophys Acta* 857, 123-126.
- Mayer L.D., Bally M.B., Hope M.J., und Cullis P.R. (1985) Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. *Biochim Biophys Acta* 816, 294-302.
- Mayhew E., Papahadjopoulos D., Rustum Y.M., und Dave C. (1976) Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles. *Cancer Res* 36, 4406-4411.
- McLaughlin S. (1989) The electrostatic properties of membranes. *Annu Rev Biophys Biophys Chem* 18, 113-136.
- Meresse S., Delbart C., Fruchart J.C., und Cecchelli R. (1989) Low-density lipoprotein receptor on endothelium of brain capillaries. *J Neurochem* 53, 340-345.
- Merrifield R.B. (1962) Peptide synthesis on a solid polymer. *Federation Proceedings* 21[2], 412.
- Miller G. (2002) Drug targeting. Breaking down barriers. *Science* 297, 1116-1118.
- Mims M.P., Darnule A.T., Tovar R.W., Pownall H.J., Sparrow D.A., Sparrow J.T., Via D.P., und Smith L.C. (1994) A nonexchangeable apolipoprotein E peptide that mediates binding to the low density lipoprotein receptor. *J Biol Chem* 269, 20539-20547.
- Monnaert V., Tilloy S., Bricout H., Fenart L., Cecchelli R., und Monflier E. (2004) Behaviour of {alpha}-, {beta}- and {gamma}-cyclodextrins and their derivatives on an in vitro model of blood brain barrier. *J Pharmacol Exp Ther.*
- Moreira J.N., Hansen C.B., Gaspar R., und Allen T.M. (2001) A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. *Biochim Biophys Acta* 1514, 303-317.
- Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 65, 55-63.

- Moulder K.L., Narita M., Chang L.K., Bu G., und Johnson E.M., Jr. (1999) Analysis of a novel mechanism of neuronal toxicity produced by an apolipoprotein E-derived peptide. *J Neurochem* 72, 1069-1080.
- Murdoch A.D., Dodge G.R., Cohen I., Tuan R.S., und Iozzo R.V. (1992) Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. *J Biol Chem* 267, 8544-8557.
- Mutschler E., Geisslinger G., and Kroemer H. S.-K. M. (2001) *Arzneimittelwirkungen*, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
- Neuwelt E.A., Frenkel E.P., Diehl J., Vu L.H., Rapoport S., und Hill S. (1980) Reversible osmotic blood-brain barrier disruption in humans: implications for the chemotherapy of malignant brain tumors. *Neurosurgery* 7, 44-52.
- New R. R. C. (1990) *Liposomes, a practical approach*, Oxford University Press.
- Nikoulin I.R. und Curtiss L.K. (1998) An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. *J Clin Invest* 101, 223-234.
- Oku N. und Namba Y. (1994) Long-circulating liposomes. *Crit Rev Ther Drug Carrier Syst* 11, 231-270.
- Oldendorf W.H. (1974) Lipid solubility and drug penetration of the blood brain barrier. *Proc Soc Exp Biol Med* 147, 813-815.
- Olson F., Hunt C.A., Szoka F.C., Vail W.J., und Papahadjopoulos D. (1979) Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. *Biochim Biophys Acta* 557, 9-23.
- Omidi Y., Campbell L., Barar J., Connell D., Akhtar S., und Gumbleton M. (2003) Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. *Brain Res* 990, 95-112.
- Omori N., Maruyama K., Jin G., Li F., Wang S.J., Hamakawa Y., Sato K., Nagano I., Shoji M., und Abe K. (2003) Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. *Neurol Res* 25, 275-279.
- Pagano R.E. und Weinstein J.N. (1978) Interactions of liposomes with mammalian cells. *Annu Rev Biophys Bioeng* 7, 435-468.
- Pardridge W. M. (1991) Peptide Drug Delivery to the Brain, (Pardridge W. M., ed.), pp. 123. Raven Press, New York.
- Pardridge W.M. (2002) Drug and gene delivery to the brain: the vascular route. *Neuron* 36, 555-558.
- Pardridge W.M. (2003) Blood-brain barrier drug targeting: the future of brain drug development. *Mol Interv* 3, 90-105, 51.

- Pardridge W.M., Boado R.J., und Farrell C.R. (1990a) Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. *J Biol Chem* 265, 18035-18040.
- Pardridge W.M., Eisenberg J., und Yang J. (1985) Human blood-brain barrier insulin receptor. *J Neurochem* 44, 1771-1778.
- Pardridge W.M., Kang Y.S., Buciak J.L., und Yang J. (1995) Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. *Pharm Res* 12, 807-816.
- Pardridge W.M. und Oldendorf W.H. (1975) Kinetic analysis of blood-brain barrier transport of amino acids. *Biochim Biophys Acta* 401, 128-136.
- Pardridge W.M., Triguero D., und Buciak J. (1989) Transport of histone through the blood-brain barrier. *J Pharmacol Exp Ther* 251, 821-826.
- Pardridge W.M., Triguero D., Buciak J., und Yang J. (1990b) Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector. *J Pharmacol Exp Ther* 255, 893-899.
- Patel D., McKinley B.D., Davis T.P., Porreca F., Yamamura H.I., und Hruby V.J. (1997) Peptide targeting and delivery across the blood-brain barrier utilizing synthetic triglyceride esters: design, synthesis, and bioactivity. *Bioconjug Chem* 8, 434-441.
- Pitas R.E., Boyles J.K., Lee S.H., Hui D., und Weisgraber K.H. (1987) Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B<sub>E</sub>(LDL) receptors in the brain. *J Biol Chem* 262, 14352-14360.
- Pitas R.E., Innerarity T.L., Arnold K.S., und Mahley R.W. (1979) Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: evidence for multiple receptor binding of apo-E HDLc. *Proc Natl Acad Sci U S A* 76, 2311-2315.
- Plank C., Zauner W., und Wagner E. (1998) Application of membrane-active peptides for drug and gene delivery across cellular membranes. *Adv Drug Deliv Rev* 34, 21-35.
- Poirier J. (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. *Trends Neurosci* 17, 525-530.
- Pool C.T. und Thompson T.E. (1998) Chain length and temperature dependence of the reversible association of model acylated proteins with lipid bilayers. *Biochemistry* 37, 10246-10255.
- Prokai L., Prokai-Tatrai K., und Bodor N. (2000) Targeting drugs to the brain by redox chemical delivery systems. *Med Res Rev* 20, 367-416.
- Rall S.C., Jr., Weisgraber K.H., und Mahley R.W. (1982) Human apolipoprotein E. The complete amino acid sequence. *J Biol Chem* 257, 4171-4178.

- Ramprasad M.P., Anantharamaiah G.M., Garber D.W., und Katre N.V. (2002) Sustained-delivery of an apolipoprotein E-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels. *J Control Release* 79, 207-218.
- Reed J. und Reed T.A. (1997) A set of constructed type spectra for the practical estimation of peptide secondary structure from circular dichroism. *Anal Biochem* 254, 36-40.
- Ren J., Lew S., Wang J., und London E. (1999) Control of the transmembrane orientation and interhelical interactions within membranes by hydrophobic helix length. *Biochemistry* 38, 5905-5912.
- Rensen P.C., de Vruh R.L., Kuiper J., Bijsterbosch M.K., Biessen E.A., und Van Berkel T.J. (2001) Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. *Adv Drug Deliv Rev* 47, 251-276.
- Rensen P.C., Herijgers N., Netscher M.H., Meskers S.C., van Eck M., und Van Berkel T.J. (1997a) Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. *J Lipid Res* 38, 1070-1084.
- Rensen P.C., Schiffelers R.M., Versluis A.J., Bijsterbosch M.K., Kuijk-Meuwissen M.E., und Van Berkel T.J. (1997b) Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. *Mol Pharmacol* 52, 445-455.
- Reyland M.E., Gwynne J.T., Forgez P., Prack M.M., und Williams D.L. (1991) Expression of the human apolipoprotein E gene suppresses steroidogenesis in mouse Y1 adrenal cells. *Proc Natl Acad Sci U S A* 88, 2375-2379.
- Riddell D.R., Graham A., und Owen J.S. (1997) Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. *J Biol Chem* 272, 89-95.
- Risau W., Engelhardt B., und Wekerle H. (1990) Immune function of the blood-brain barrier: incomplete presentation of protein (auto-)antigens by rat brain microvascular endothelium in vitro. *J Cell Biol* 110, 1757-1766.
- Rivnay B., Bayer E.A., und Wilchek M. (1987) Use of avidin-biotin technology for liposome targeting. *Methods Enzymol* 149, 119-123.
- Rousselle C., Clair P., Lefauconnier J.M., Kaczorek M., Scherrmann J.M., und Tamsamani J. (2000) New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. *Mol Pharmacol* 57, 679-686.
- Rousselle C., Clair P., Tamsamani J., und Scherrmann J.M. (2002) Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy. *J Drug Target* 10, 309-315.
- Rousselle C., Smirnova M., Clair P., Lefauconnier J.M., Chavanieu A., Calas B., Scherrmann J.M., und Tamsamani J. (2001) Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. *J Pharmacol Exp Ther* 296, 124-131.

- Roux F., Durieu-Trautmann O., Chaverot N., Claire M., Mailly P., Bourre J.M., Strosberg A.D., und Couraud P.O. (1994) Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. *J Cell Physiol* 159, 101-113.
- Rubin L.L. und Staddon J.M. (1999) The cell biology of the blood-brain barrier. *Annu Rev Neurosci* 22, 11-28.
- Sanovich E., Bartus R.T., Friden P.M., Dean R.L., Le H.Q., und Brightman M.W. (1995) Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. *Brain Res* 705, 125-135.
- Scheller A., Oehlke J., Wiesner B., Dathe M., Krause E., Beyermann M., Melzig M., und Bienert M. (1999) Structural requirements for cellular uptake of alpha-helical amphipathic peptides. *J Pept Sci* 5, 185-194.
- Schmid S.L. und Carter L.L. (1990) ATP is required for receptor-mediated endocytosis in intact cells. *J Cell Biol* 111, 2307-2318.
- Schroeder H., Leventis R., Rex S., Schelhaas M., Nagele E., Waldmann H., und Silvius J.R. (1997) S-Acylation and plasma membrane targeting of the farnesylated carboxyl-terminal peptide of N-ras in mammalian fibroblasts. *Biochemistry* 36, 13102-13109.
- Schwarze S.R., Ho A., Vocero-Akbani A., und Dowdy S.F. (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. *Science* 285, 1569-1572.
- Seelig J. (1997) Titration calorimetry of lipid-peptide interactions. *Biochim Biophys Acta* 1331, 103-116.
- Seetharaman S., Barrand M.A., Maskell L., und Scheper R.J. (1998) Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. *J Neurochem* 70, 1151-1159.
- Sessa G. und Weissmann G. (1968) Phospholipid spherules (liposomes) as a model for biological membranes. *J Lipid Res* 9, 310-318.
- Simmons T., Newhouse Y.M., Arnold K.S., Innerarity T.L., und Weisgraber K.H. (1997) Human low density lipoprotein receptor fragment. Successful refolding of a functionally active ligand-binding domain produced in Escherichia coli. *J Biol Chem* 272, 25531-25536.
- Srinivasan S.R., Dolan P., Radhakrishnamurthy B., und Berenson G.S. (1972) Isolation of lipoprotein-acid mucopolysaccharide complexes from fatty streaks of human aortas. *Atherosclerosis* 16, 95-104.
- Storm G., Roerdink F.H., Steerenberg P.A., de Jong W.H., und Crommelin D.J. (1987) Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. *Cancer Res* 47, 3366-3372.
- Straubinger R.M., Sharma A., Murray M., und Mayhew E. (1993) Novel Taxol formulations: Taxol-containing liposomes. *J Natl Cancer Inst Monogr* 69-78.
- Szoka F., Jr. und Papahadjopoulos D. (1980) Comparative properties and methods of preparation of lipid vesicles (liposomes). *Annu Rev Biophys Bioeng* 9, 467-508.

- Tatsuta T., Naito M., Oh-hara T., Sugawara I., und Tsuruo T. (1992) Functional involvement of P-glycoprotein in blood-brain barrier. *J Biol Chem* 267, 20383-20391.
- Thöle M., Nobmanna S., Huwyler J., Bartmann A., und Fricker G. (2002) Uptake of cationized albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. *J Drug Target* 10, 337-344.
- Torchilin V.P. (1985) Liposomes as targetable drug carriers. *Crit Rev Ther Drug Carrier Syst* 2, 65-115.
- Torchilin V.P., Rammohan R., Weissig V., und Levchenko T.S. (2001) TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. *Proc Natl Acad Sci U S A* 98, 8786-8791.
- Tyagi M., Rusnati M., Presta M., und Giacca M. (2001) Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. *J Biol Chem* 276, 3254-3261.
- Ulrich A.S. (2002) Biophysical aspects of using liposomes as delivery vehicles. *Biosci Rep* 22, 129-150.
- Urien S., Pinquier J.L., Paquette B., Chaumet-Riffaud P., Kiechel J.R., und Tillement J.P. (1987) Effect of the binding of isradipine and darodipine to different plasma proteins on their transfer through the rat blood-brain barrier. Drug binding to lipoproteins does not limit the transfer of drug. *J Pharmacol Exp Ther* 242, 349-353.
- van Gelder W., Cleton-Soeteman M.I., Huijskes-Heins M.I., van Run P.R., und van Eijk H.G. (1997) Transcytosis of 6.6-nm gold-labeled transferrin: an ultrastructural study in cultured porcine blood-brain barrier endothelial cells. *Brain Res* 746, 105-116.
- Vasile E., Simionescu M., und Simionescu N. (1983) Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ. *J Cell Biol* 96, 1677-1689.
- Versluis A.J., Rensen P.C., Rump E.T., Van Berkel T.J., und Bijsterbosch M.K. (1998) Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes. *Br J Cancer* 78, 1607-1614.
- Versluis A.J., Rump E.T., Rensen P.C., Van Berkel T.J., und Bijsterbosch M.K. (1999) Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. *J Pharmacol Exp Ther* 289, 1-7.
- Vives E., Brodin P., und Lebleu B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. *J Biol Chem* 272, 16010-16017.
- Vorbrodt A.W. und Dobrogowska D.H. (2003) Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist's view. *Brain Res Brain Res Rev* 42, 221-242.
- Wang G., Pierens G.K., Treleaven W.D., Sparrow J.T., und Cushley R.J. (1996) Conformations of human apolipoprotein E(263-286) and E(267-289) in aqueous solutions of sodium dodecyl sulfate by CD and <sup>1</sup>H NMR. *Biochemistry* 35, 10358-10366.

- Wang X., Ciruolo G., Morris R., und Gruenstein E. (1997) Identification of a neuronal endocytic pathway activated by an apolipoprotein E (apoE) receptor binding peptide. *Brain Res* 778, 6-15.
- Weisgraber K. H. (1994) Apolipoprotein E: Structure-Funktion Relationships, in *Advances in Protein Chemistry* pp. 249-369.
- Weisgraber K.H., Innerarity T.L., Harder K.J., Mahley R.W., Milne R.W., Marcel Y.L., und Sparrow J.T. (1983) The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. *J Biol Chem* 258, 12348-12354.
- Weisgraber K.H., Rall S.C., Jr., Mahley R.W., Milne R.W., Marcel Y.L., und Sparrow J.T. (1986) Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. *J Biol Chem* 261, 2068-2076.
- Wetterau J.R., Aggerbeck L.P., Rall S.C., Jr., und Weisgraber K.H. (1988) Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. *J Biol Chem* 263, 6240-6248.
- Wieprecht T., Beyermann M., und Seelig J. (1999) Binding of antibacterial magainin peptides to electrically neutral membranes: thermodynamics and structure. *Biochemistry* 38, 10377-10387.
- Wieprecht T., Dathe M., Schumann M., Krause E., Beyermann M., und Bienert M. (1996) Conformational and functional study of magainin 2 in model membrane environments using the new approach of systematic double-D-amino acid replacement. *Biochemistry* 35, 10844-10853.
- Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., und Agard D.A. (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. *Science* 252, 1817-1822.
- Wimley W.C. und White S.H. (2000) Designing transmembrane alpha-helices that insert spontaneously. *Biochemistry* 39, 4432-4442.
- Wolburg H. und Lippoldt A. (2002) Tight junctions of the blood-brain barrier: development, composition and regulation. *Vascul Pharmacol* 38, 323-337.
- Woodle M.C., Newman M.S., und Cohen J.A. (1994) Sterically stabilized liposomes: physical and biological properties. *J Drug Target* 2, 397-403.
- Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., und Dewhirst M.W. (1993) Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. *Cancer Res* 53, 3765-3770.
- Yanagishita M. und Hascall V.C. (1992) Cell surface heparan sulfate proteoglycans. *J Biol Chem* 267, 9451-9454.
- Zabner J. (1997) Cationic lipids used in gene transfer. *Adv Drug Deliv Rev* 27, 17-28.
- Zhang X., Xie J., Li S., Wang X., und Hou X. (2003) The study on brain targeting of the amphotericin B liposomes. *J Drug Target* 11, 117-122.

Zhang Y., Zhu C., und Pardridge W.M. (2002) Antisense gene therapy of brain cancer with an artificial virus gene delivery system. *Mol Ther* 6, 67-72.

Zlokovic B.V. und Apuzzo M.L. (1998) Strategies to circumvent vascular barriers of the central nervous system. *Neurosurgery* 43, 877-878.